FibroBiologics (FBLG) News Today $0.94 -0.01 (-0.93%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.92 -0.02 (-1.71%) As of 06/10/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FBLG Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period FibroBiologics Appoints Jason D. Davis as CFOJune 9 at 4:51 PM | tipranks.comFibrobiologics, Inc.: FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial OfficerJune 9 at 2:45 PM | finanznachrichten.deFibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial OfficerJune 9 at 8:30 AM | globenewswire.comFibroBiologics, Inc. (NASDAQ:FBLG) Insider Hamid Khoja Purchases 20,000 SharesMay 28, 2025 | insidertrades.comFBLG: Poster Presentation Shows Potential for Fibroblast Therapy in Psoriasis…May 22, 2025 | msn.comPromising Potential for FibroBiologics, Inc. in Regenerative Medicine with Innovative Fibroblast-Based TherapiesMay 17, 2025 | tipranks.comFibroBiologics Presents at the Society for Investigative Dermatology Annual MeetingMay 16, 2025 | globenewswire.comFibrobiologics, Inc.: FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | finanznachrichten.deFibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comFibroBiologics Says Robert Hoffman to Step Down as Interim CFOMay 5, 2025 | marketwatch.comFibroBiologics Presenting at the ThymUS 2025 MeetingApril 29, 2025 | globenewswire.comFibroBiologics to Present at The Cell & Gene Meeting on the MediterraneanApril 11, 2025 | globenewswire.comOTC Markets Hosts Virtual Investor Presentation with Pete O'Heeron, CEO & Chairman of FibroBiologics, Inc., with David Bautz, PhD, Senior Analyst at Zacks SCRApril 9, 2025 | msn.comFibroBiologics announces opening of new lab facilityApril 9, 2025 | markets.businessinsider.comFibroBiologics Unveils New and Expanded Houston Laboratory Space to Pursue Innovation and Breakthroughs in Fibroblast-Based TherapeuticsApril 8, 2025 | globenewswire.comFibroBiologics Reports 2024 Financial Results and UpdatesApril 4, 2025 | tipranks.comFBLG: Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25…April 3, 2025 | finance.yahoo.comFibroBiologics announces advancement in results of brain tissue repairApril 3, 2025 | markets.businessinsider.comFibroBiologics Announces Scientific Advancement in Confirmation Results of Brain Tissue RepairApril 2, 2025 | globenewswire.comFibroBiologics Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | globenewswire.comFibroBiologics Announces 2025 Annual Meeting of StockholdersMarch 27, 2025 | globenewswire.comFibroBiologics to Present at The German-Nordic Joint Extracellular Matrix MeetingMarch 21, 2025 | globenewswire.comFibroBiologics files patent application for fibroblast-based therapeuticsMarch 4, 2025 | markets.businessinsider.comFibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based TherapeuticsMarch 4, 2025 | globenewswire.comFibroBiologics Inc. FBLG (U.S.: Nasdaq)March 1, 2025 | wsj.comFibroBiologics and Charles River Announce Completion and Release of CYWC628 Master Cell Bank for the Manufacturing of Fibroblast Cell-based Wound Healing TherapeuticFebruary 27, 2025 | globenewswire.comFBLG: Analyst Day Provides In-Depth Overview of Pipeline…February 24, 2025 | msn.comFibroBiologics (NASDAQ:FBLG) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of FibroBiologics in a report on Thursday.February 13, 2025 | marketbeat.comFibroBiologics issues shares to fulfill commitment feeFebruary 8, 2025 | msn.comFibroBiologics to Host In-Person Analyst Day to Provide Research & Development UpdatesFebruary 5, 2025 | globenewswire.comFibroBiologics files $50M mixed securities shelfFebruary 4, 2025 | markets.businessinsider.comFibroBiologics Approves Executive Bonuses for 2024January 24, 2025 | tipranks.comGeode Capital Management LLC Acquires 284,047 Shares of FibroBiologics, Inc. (NASDAQ:FBLG)Geode Capital Management LLC grew its holdings in FibroBiologics, Inc. (NASDAQ:FBLG - Free Report) by 90.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 599,760 shares of the company's stock after buying an additional 284,047 shares during theJanuary 9, 2025 | marketbeat.comFibroBiologics Secures $5M Funding for Strategic GrowthDecember 31, 2024 | tipranks.comFibroBiologics files to sell 41.3M shares of common stock for holdersDecember 31, 2024 | markets.businessinsider.comFibroBiologics Closes Second $5 Million Tranche of $25 Million FinancingDecember 30, 2024 | globenewswire.comD. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million FinancingDecember 30, 2024 | investing.comD. Boral Capital Served as Exclusive Placement Agent to FibroBiologics, Inc. (Nasdaq: FBLG) in connection with its $25.0 Million FinancingDecember 30, 2024 | globenewswire.comFibroBiologics' (FBLG) "Buy" Rating Reiterated at D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and issued a $16.00 price target on shares of FibroBiologics in a report on Friday.December 27, 2024 | marketbeat.comFibroBiologics announces $25M financingDecember 23, 2024 | markets.businessinsider.comFibroBiologics Announces $25 Million FinancingDecember 23, 2024 | globenewswire.comFibroBiologics Resolves Commitments Through Share Issuance AgreementDecember 20, 2024 | tipranks.comFibroBiologics, Inc. (NASDAQ:FBLG) Short Interest UpdateFibroBiologics, Inc. (NASDAQ:FBLG - Get Free Report) was the recipient of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 2,700,000 shares, an increase of 6.7% from the November 15th total of 2,530,000 shares. Based on an average daily volume of 376,500 shares, the days-to-cover ratio is presently 7.2 days. Currently, 10.2% of the company's shares are sold short.December 17, 2024 | marketbeat.comRodman & Renshaw Initiates Coverage of FibroBiologics (FBLG) with Buy RecommendationDecember 12, 2024 | msn.comFibroBiologics initiated with a Buy at Rodman & RenshawDecember 12, 2024 | markets.businessinsider.comRodman & Renshaw Initiates Coverage on FibroBiologics (NASDAQ:FBLG)Rodman & Renshaw started coverage on shares of FibroBiologics in a research report on Thursday. They set a "buy" rating and a $12.00 price target for the company.December 12, 2024 | marketbeat.comShort Interest in FibroBiologics, Inc. (NASDAQ:FBLG) Increases By 7.2%FibroBiologics, Inc. (NASDAQ:FBLG - Get Free Report) saw a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 2,530,000 shares, a growth of 7.2% from the October 31st total of 2,360,000 shares. Approximately 9.4% of the company's stock are short sold. Based on an average daily volume of 402,500 shares, the short-interest ratio is currently 6.3 days.December 3, 2024 | marketbeat.comFibroBiologics seeks patent for spleen disorder treatmentNovember 21, 2024 | investing.comFBLG: On Target to Initiate Phase 1/2 Trial in 2025…November 21, 2024 | finance.yahoo.comFibroBiologics files patent application for cell-based therapeuticNovember 19, 2024 | markets.businessinsider.com Get FibroBiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter. Email Address FBLG Media Mentions By Week FBLG Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FBLG News Sentiment▼0.641.01▲Average Medical News Sentiment FBLG News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FBLG Articles This Week▼41▲FBLG Articles Average Week Get FibroBiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for FBLG and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CTNM News Today KYTX News Today ATOS News Today IVVD News Today BHST News Today SGMT News Today PROC News Today IOBT News Today CABA News Today IMAB News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FBLG) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroBiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroBiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
